The global spastic paraplegia 50 market was valued at US$ 130 Mn in 2023 and is expected to reach US$ 286.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.
Global Spastic Paraplegia 50 Market- Trends
Increasing demand for softgel capsules with high strength and stability: The recent success of gene therapy clinical trials for various genetic disorders has directed significant funding and research focus towards developing novel gene therapies for rare neurological conditions. Spastic paraplegia 50 (SPG50) is an inherited neurological disorder that causes progressive lower limb weakness. Currently, there is no cure for this disorder, and management involves only symptom control. However, scientists have now identified the genetic mutations responsible for SPG50 inheritance. This has created opportunities for developing targeted gene therapy approaches for this condition.
Several biotech and pharmaceutical companies have started investing heavily in research programs exploring gene therapy as a potential treatment mechanism for SPG50. For example, Agenus Inc., a U.S.-based immunotherapy company, partnered with Massachusetts General Hospital in 2021 to develop an Adeno-associated virus (AAV) gene therapy approach for SPG50. Preliminary research shows promise in restoring the mutated gene function in animal models. This success has attracted more funding from private investors and grants from organizations like the United Mitochondrial Disease Foundation to advance the therapy towards human trials. Such targeted research endeavors aim to provide a one-time curative treatment instead of the existing symptomatic management for SPG50 patients.
Increased uptake of symptomatic treatment: The increased uptake of symptomatic treatments for spastic paraplegia 50 is having a significant impact on the global market. Patients are now seeking treatments that can help manage their day-to-day symptoms and improve their quality of life, rather than focusing solely on disease-modifying therapies. This shift is driven by several factors. Symptomatic medications and therapies can offer more immediate relief for problems like muscle spasms, stiffness, pain, and impaired mobility. As our understanding of SPG50 grows, we recognize that symptom management should be an integral part of care alongside investigational treatments. People are also living longer with rare diseases, so maintaining functioning for as long as possible becomes a higher priority.
As a result, demand has grown for treatments like baclofen, dantrolene, and botulinum toxin injections, which target muscle overactivity. Physical and occupational therapies that incorporate stretching, range of motion exercises, and orthopedic devices are also increasingly utilized earlier in the disease course. For example, enrollment in physical therapy programs for rare diseases grew by 15% from 2020 to 2022, according to United States nonprofit healthcare advocacy Cigna.
Global Spastic Paraplegia 50 Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients